UA51263A - Способ лечения больных гриппом - Google Patents
Способ лечения больных гриппом Download PDFInfo
- Publication number
- UA51263A UA51263A UA2002021108A UA200221108A UA51263A UA 51263 A UA51263 A UA 51263A UA 2002021108 A UA2002021108 A UA 2002021108A UA 200221108 A UA200221108 A UA 200221108A UA 51263 A UA51263 A UA 51263A
- Authority
- UA
- Ukraine
- Prior art keywords
- influenza
- patients
- treatment
- day
- patient
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 30
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 12
- 230000000286 interferogenic effect Effects 0.000 claims abstract description 7
- 238000012876 topography Methods 0.000 claims 1
- 208000002193 Pain Diseases 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- ILSOAHPXYZRFBA-UHFFFAOYSA-N n-benzyl-1-methylpyridin-1-ium-4-carboxamide;iodide Chemical compound [I-].C1=C[N+](C)=CC=C1C(=O)NCC1=CC=CC=C1 ILSOAHPXYZRFBA-UHFFFAOYSA-N 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- 206010019233 Headaches Diseases 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000002519 immonomodulatory effect Effects 0.000 description 6
- 230000036760 body temperature Effects 0.000 description 5
- 208000017574 dry cough Diseases 0.000 description 5
- 206010025482 malaise Diseases 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000001871 Tachycardia Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000001754 anti-pyretic effect Effects 0.000 description 4
- 210000005252 bulbus oculi Anatomy 0.000 description 4
- 206010039083 rhinitis Diseases 0.000 description 4
- 230000006794 tachycardia Effects 0.000 description 4
- 206010025327 Lymphopenia Diseases 0.000 description 3
- 208000000112 Myalgia Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000001983 hard palate Anatomy 0.000 description 2
- 201000000615 hard palate cancer Diseases 0.000 description 2
- 230000000544 hyperemic effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000001989 nasopharynx Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960000888 rimantadine Drugs 0.000 description 2
- 210000001584 soft palate Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 229960004626 umifenovir Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- RKPSOUZGYPZAHW-UHFFFAOYSA-N adapromine Chemical compound C1C(C2)CC3CC2CC1(C(N)CC)C3 RKPSOUZGYPZAHW-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения больных гриппом включает в себя введение препаратов с интерфероногенной активностью. Дополнительно применяют амизон по 0,25 г 3-4 раза в день внутрь на протяжении 5-7 дней подряд.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002021108A UA51263A (ru) | 2002-02-12 | 2002-02-12 | Способ лечения больных гриппом |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002021108A UA51263A (ru) | 2002-02-12 | 2002-02-12 | Способ лечения больных гриппом |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA51263A true UA51263A (ru) | 2002-11-15 |
Family
ID=74246529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002021108A UA51263A (ru) | 2002-02-12 | 2002-02-12 | Способ лечения больных гриппом |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA51263A (ru) |
-
2002
- 2002-02-12 UA UA2002021108A patent/UA51263A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201827044A (zh) | 用於治療發炎性腸病的組合物 | |
| UA51263A (ru) | Способ лечения больных гриппом | |
| RU2632443C1 (ru) | Способ лечения билиарного сладжа у больных хроническим билиарнозависимым панкреатитом | |
| Negovetić Vranić et al. | Hitna stanja u dječjoj stomatologiji | |
| RU2329803C1 (ru) | Способ лечения туберкулеза легких | |
| US20170349438A1 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| RU2271233C1 (ru) | Способ лечения больных бронхиальной астмой | |
| RU2468813C1 (ru) | Средство для профилактики или лечения острых и хронических нарушений мозгового кровообращения, применение и способ лечения | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome | |
| RU2401123C2 (ru) | Способ лечения псориаза у детей | |
| Persley et al. | Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis | |
| JP2017031144A (ja) | 経口用医薬組成物 | |
| Davidson et al. | The treatment of congenital syphilis with stovarsol | |
| UA70015A (en) | Method for treating influenza in adults | |
| Kassirer et al. | A surprising cause of abdominal pain, anorexia, vomiting, and weight loss | |
| CONFIRM | WIDE MARGIN | |
| CN113015524A (zh) | 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途 | |
| Ravi et al. | Commonly Discussed But Rarely Seen | |
| UA78247C2 (en) | Method for treating chronic alcoholic pancreatitis in setting of ischemic heart disease | |
| UA65097A (en) | Method for treating acute respiratory infections in adults | |
| Stott | Studies in Malaria: Oral Quinine in Malaria | |
| JPWO2005027968A1 (ja) | ダウン症候群治療剤 | |
| UA17882U (en) | Method for treating patients with increased fatigue syndrome in setting of chronic tonsillitis | |
| Chatterjee | PLAB 1 Revision Book: Extended Matching Questions and Single Best Answer Questions | |
| Cheney | SALVARSAN IN VARIOUS MEDICAL DISORDERS ASSOCIATED WITH A WASSERMANN REACTION |